Clinical efficacy and safety of regorafenib in the treatment of colorectal cancer

Regorafenib is an oral multi-target tyrosine kinase inhibitor widely used in the treatment of patients with advanced colorectal cancer. Its mechanism of action mainly inhibits tumor growth by inhibiting multiple kinases, such as VEGFR, PDGFR and RAF, blocking tumor angiogenesis and tumor cell proliferation signals. Clinical trials have shown that regorafenib has certain efficacy in patients with metastatic colorectal cancer who have previously received a variety of standard treatments, and can significantly extend progression-free survival and overall survival.

Multiple clinical studies have shown that regorafenib exhibits positive efficacy in the treatment of advanced colorectal cancer. For example, in the CORRECT trial, the median overall survival of patients in the regorafenib group was significantly better than that in the placebo group, and progression-free survival was prolonged. The patient's tumor burden was reduced and his condition was effectively controlled. Especially after standard treatments fail, regorafenib provides patients with new treatment options and improves the quality of life and survival time of advanced patients.

Although regorafenib shows advantages in terms of efficacy, its safety issues also need to be paid attention to. Common adverse reactions include hand-foot syndrome, hypertension, fatigue, diarrhea and loss of appetite. These side effects may affect patients' treatment compliance and quality of life. Clinically, the monitoring and management of patients should be strengthened, and the dosage should be adjusted in a timely manner or supportive treatment measures should be taken to reduce the adverse effects caused by side effects and ensure the continuity and safety of treatment.
In summary, regorafenib, as a second-line or multi-line treatment for advanced colorectal cancer, plays an important role in prolonging patient survival and controlling tumor progression due to its multi-target inhibitory effect. However, doctors should reasonably evaluate the efficacy and risks based on the patient's specific situation, formulate an individualized treatment plan, balance the efficacy and side effects, and improve the patient's overall treatment effect and quality of life.
Reference: https://www.stivarga-us.com/